MyoKardia, Inc. is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. 

About Cardiomyopathies

Heartbeats: A Conversation with The Hypertrophic Cardiomyopathy Experts

News & Events

August 7, 2017
MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Link

August 7, 2017
MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress
Link

May 9, 2017
MyoKardia Reports First Quarter 2017 Financial Results and Operational Progress
Link

April 18, 2017
MyoKardia Appoints David Meeker, M.D., to Board of Directors
Link